Reporting on Adverse Clinical Events

In a prospective observational study, the incidence of adverse events was examined in 438 hemodialysis (HD) patients who received 3 doses of COVID-19 vaccines. Most patients included in the analysis received Oxford/AstraZeneca ChAdOx1 as the first 2 doses and Moderna mRNA1273 as the third dose. Overall, 79%, 50%, and 84% of the patients experienced at least 1 adverse event after the first, second, and third doses, respectively. Most reactions were minor and temporary. Compared with the first dose, the second dose was associated with a lower rate of adverse events and the third dose was associated with a higher rate of local injection site reactions but a lower rate of systemic effects. Further analysis indicated that characteristics associated with increased risk of adverse events included female sex (odds ratio [OR]: 2.82; 95% confidence interval [CI]: 1.90-4.18) and arteriovenous fistula access (OR: 1.73; 95% CI: 1.05-2.84). Based on the results of this prospective observational study in HD patients, the authors concluded that COVID-19 vaccination was generally well tolerated. Factors associated with increased risk of adverse events included female sex and arteriovenous fistula access. COVID Vaccine [ChAdOx1, mRNA-1273] Pai MF et al (Wan-Chuan Tsai: Division of Nephrology, Department of Internal Medicine; Center for General Education, Lee-Ming Institute of Technology, Far Eastern Memorial Hospital, No. 21, Section 2, Nanya South Road, Banciao District, New Taipei City 220, New Taipei City, Taiwan; e-mail: mkks618@gmail.com) Adverse events following the first, second and third doses of a COVID-19 vaccine in hemodialysis patients. Ren Fail 45:2172432 (Dec) 2023